Plain-English translation of NCT05441267 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Diabetes Mellitus, Type 2 research guide →Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
ASCEND PLUS is testing whether a medication called oral semaglutide can help prevent serious heart problems in people with type 2 diabetes. The study will involve over 21,000 participants and will be conducted entirely online—you won't need to visit a clinic in person. The medication will be mailed to your home, and your health will be tracked through NHS records for up to 25 years.
Many people with type 2 diabetes have heart attacks or strokes, even when their blood sugar is well controlled. Researchers want to know if this medication can help prevent these serious events in people who haven't had them before.
You'll start by taking the medication at increasing doses for 8–12 weeks to see how you tolerate it. If you do well, you'll be randomly assigned to either take 14mg of the medication daily or a placebo (inactive pill), with the option to reduce to 7mg if needed. All medication will be mailed to your home, and you'll be contacted through a secure website, phone calls, video calls, or letters. The trial is expected to last about 5 years, and your health will continue to be monitored through NHS records for 20 years after the main treatment period ends.
AI-generated summary from trial data · Jun 29, 2026 · Not medical advice
United Kingdom